SOURCE: Elsevier Business Intelligence

Elsevier Business Intelligence

November 18, 2013 08:00 ET

Therapeutic Area Partnerships Meeting Investigates Solutions to the Disparity Between Improving Science and Declining Returns

BEDMINSTER, NJ--(Marketwired - Nov 18, 2013) - Elsevier Business Intelligence hosts the 8th Annual Therapeutic Area Partnerships (TAP) at The Hyatt Regency in Boston, MA on November 18-20, 2013, the most efficient and highest quality biopharmaceutical industry meeting of its kind.

Jack Scannell, Head of Discovery Research, e-Therapeutics Plc, Former Senior Analyst Sanford C. Bernstein and Former Consultant Boston Consulting Group, will give a keynote address on "Boosting R&D Productivity: Rethinking the Disparity Between Improving Science and Declining Returns." The author of a controversial and widely read paper on the subject, Scannell will examine why the pharmaceutical industry cannot overcome its troubling mismatch between scientific advances and R&D returns. He asserts that many technology advances industrialize and "optimize" the wrong set of activities. Understanding how and why the industry routinely over-estimates its ability to design drugs has important implications for investment and portfolio management.

After Scannell's talk, he along with AstraZeneca's Kumar Srinivasan, VP, Scientific Partnering & Alliances; John Gustofson, AbbVie's Senior Director of Ventures & Early Stage Collaborations; and David Deperthes, VP, Business Development & Licensing at Debiopharm International, will hold a Roundtable Discussion and Q&A session on "Rethinking Solutions to the R&D Productivity Crisis" to explore how the industry is working to reverse the trend towards lower returns on R&D investment. These leaders will offer their strategic insights for an industry in transition.

TAP offers attendees the most efficient and intimate industry gathering of its kind. Each year respected independent experts rigorously review projects from around the world available for partnering, and select the Top 10 Projects in Oncology, Cardiovascular/Metabolic Diseases, Neuroscience, Infectious Diseases, Autoimmune/Anti-Inflammatory Diseases, and Advanced Therapies (Gene Therapy, Cell Therapy, Rare Diseases, etc.). Each clinical advisor will explain the current trends within the therapeutic area, the Top 10 selection process and why these companies offer significant opportunities. Many presenting companies from previous years have gone on to establish major partnerships.

TAP is a one-of-a-kind opportunity to assess some of the most promising drugs in development and available for partnering. Decision-makers, investors, analysts, and entrepreneurs can hear from a spectrum of high quality companies and meet to develop strategic alliances. All attendees can utilize the meeting's partnering software to conduct research on companies attending the conference, schedule one-on-one meetings with prospective partners, and showcase their company's innovative technology and investment/partnering interests.

TAP attendees will have real opportunities to meet decision-makers interested in acquisitions and alliances. For more information or to register for this event, visit

About Elsevier Business Intelligence
Elsevier Business Intelligence, a global leader in the field of healthcare industry information, provides business intelligence on regulatory, business and reimbursement issues that are vital to the healthcare industry. Through a range of products including publications, conferences, e-learning, databases and reports, Elsevier Business Intelligence places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge, by providing the perfect combination of news and information together with penetrating insight and analysis. Our leading publications include PharmAsia News, IN VIVO and "The Pink Sheet." For more information, visit:

Contact Information

  • Media contact
    Mike Fergus
    Elsevier Business Intelligence
    Email Contact